Preclinical and first-in-human safety studies on a novel magnetism-based haemofiltration method

Nicole Waalders,Dirk van Lier,Jelle Gerretsen,Lucy Moran,Kerstin A. Stegmann,Will Twigger,Cristina Blanco-Andujar,George Frodsham,Matthijs Kox,Peter Pickkers

DOI: https://doi.org/10.1038/s41598-024-64379-9

IF: 4.6

2024-06-20

Scientific Reports

Abstract:Extracorporeal haemofiltration devices that selectively remove cytokines could represent an adjunctive treatment in inflammatory diseases. One such device is the "IL-6-Sieve", wherein magnetic Anti-IL-6 Beads are introduced into an extracorporeal circuit via a Bead Adapter and then removed along with any surface-bound interleukin (IL)-6 by a Filter deployed in a Magnet, before the blood is returned to the patient. We report here on a series of animal studies, and a first-in-human study, on the safety of the IL-6-Sieve. Evaluations focused on the: (a) safety of Filter and Magnet placed in an extracorporeal circuit in sheep; (b) safety of Anti-IL-6 Beads—directly infused intravenously as worst case scenario of misuse; or injected into an extracorporeal circuit using the Bead Adapter, Filter, and Magnet as intended—in sheep; (c) biodistribution of Anti-IL-6 Beads intravenously infused in mice; and (d) safety of Filter and Magnet placed in an extracorporeal circuit in healthy volunteers. No serious adverse events or significant changes in vital signs or routine laboratory parameters occurred in any of the animals or humans. Although safety of the IL-6-Sieve requires further study, these initial evaluations represent a promising start for the translation of this new blood purification modality into clinical use.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to safely and effectively remove cytokines (such as IL - 6) in the blood through a new magnetic hemofiltration method (called "IL - 6 - Sieve") in acute inflammatory diseases, especially sepsis, thereby reducing excessive inflammatory responses and improving the clinical prognosis of patients. Specifically, the study focused on the following aspects:

1. **Safety of filters and magnets**: The safety of placing filters and magnets in an extracorporeal circulation loop was evaluated in sheep.
2. **Safety of anti - IL - 6 beads**: The safety of anti - IL - 6 beads when directly injected intravenously (in the worst - case scenario of misuse) or when used as expected through bead adapters, filters, and magnets was evaluated.
3. **Biodistribution of anti - IL - 6 beads**: The biodistribution of anti - IL - 6 beads after direct intravenous injection was evaluated in mice.
4. **Human safety**: The safety of placing filters and magnets in an extracorporeal circulation loop was evaluated in healthy volunteers.

These studies aim to provide preliminary safety data for the clinical application of this new blood purification technology and lay the foundation for further clinical trials.